PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.1 CNY | +0.71% |
|
+5.10% | -32.01% |
| Sales 2024 * | 3.88B 537M 734M | Sales 2025 * | 4.78B 661M 903M | Capitalization | 9.34B 1.29B 1.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 445M 61.54M 84.05M | Net income 2025 * | 606M 83.8M 114M | EV / Sales 2024 * | 2.4 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.95 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
15.4
x | Employees | 4,915 |
| Yield 2024 * |
1.24% | Yield 2025 * |
1.61% | Free-Float | 56.08% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.71% | ||
| 1 week | +5.10% | ||
| Current month | -4.47% | ||
| 1 month | -4.47% | ||
| 3 months | -11.31% | ||
| 6 months | -40.31% | ||
| Current year | -32.01% |
1 week
16.10
17.22
1 month
15.8518.47
Current year
14.7125.25
1 year
14.7134.58
3 years
14.71109.77
5 years
7.45109.77
10 years
7.04109.77
| Managers | Title | Age | Since |
|---|---|---|---|
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Chen
DFI | Director of Finance/CFO | 45 | 22-04-21 |
Yong Qing Tan
CHM | Chairman | 69 | 19-04-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Gang Yuan
BRD | Director/Board Member | 57 | 21-08-04 |
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Zeng
BRD | Director/Board Member | 44 | 10-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 17.1 | +0.71% | 12,821,250 |
| 24-04-26 | 16.98 | +2.10% | 7,794,401 |
| 24-04-25 | 16.63 | +1.59% | 6,761,063 |
| 24-04-24 | 16.37 | -0.37% | 4,610,417 |
| 24-04-23 | 16.43 | +0.98% | 5,589,259 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.1
CNY
Average target price
28.5
CNY
Spread / Average Target
+66.67%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.01% | 1.28B | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- 300363 Stock
